12:00noon Monday 6th July
Room 208, 2nd floor,
Microbiology building,
720 Cumberland Street
Microbiology and Immunology, University of Otago
Seneca Valley Virus (SVV) is a newly-discovered oncolytic virus and has currently completed phase I and phase II clinical trials in paediatric solid tumors and small-cell lung cancer, respectively. Recently, we identified the Anthrax Toxin Receptor 1 (ANTXR1) as the high-affinity cellular receptor for SVV in cancer cells. However, the high-resolution structural information on SVV capsid architecture and SVV-ANTXR1 interaction sites remained poorly characterised, thereby hampering the potential to develop SVV mutants in future oncovirotherapy. This seminar will cover structural details on SVV mature virion, empty capsid architectures and their interactions with ANTXR1, providing a plausible explanation for SVV’s exquisite tumor specificity. Furthermore, I will present a bio-selection methodology our lab employed to isolate and characterise stable SVV capsids, which could prove to be beneficial in future therapeutics.
